TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1867232
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg/day
Study: 7572686
Drug: Lovastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20-40 mg/day)
Study: 1831006
Drug: Lovastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (80 mg/day)
Study: 6861303
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (daily prescribed physical exercise for 60 days)
Study: 29746823
Drug: Behavior-change intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavior-change intervention (weekly 30-minute telephone sessions for 12 weeks)
Study: 23706899
Drug: Venlafaxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine treatment
Study: 17180128
Drug: Test solution
Normalized name: Candin Skin Test Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solution (sterile, isotonic solution patterned after human amniotic fluid), 2.5 ml/kg every 3 hours via OG/NG tube for up to 7 days.
Study: 17180128
Drug: Sham administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham administration (control), every 3 hours via OG/NG tube for up to 7 days.
Study: 17180128
Drug: Test solution
Normalized name: Candin Skin Test Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test solution (compared to sham),
Study: 15677431
Drug: Prolactin-elevating antipsychotics
Normalized name: prolactin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolactin-elevating antipsychotics (control)
Study: 2943811
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant hepatitis B vaccine
Study: 25230741
Drug: Catechin-rich green
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catechin-rich green tea (615 mg/350 ml)
Study: 25230741
Drug: Placebo (92
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (92 mg/350 ml)
Study: 11703992
Drug: Azimilide 100
Normalized name: Azimilide
DrugBank: Azimilide (DB04957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide 100 mg/day
Study: 11703992
Drug: Azimilide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azimilide (100 and 125 mg/day)
Study: 9627377
Drug: Tall oil
Normalized name: TALL OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tall oil phytosterols (21.2 mg/kg body weight/d)
Study: 2778240
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (20 mg three times daily)
Study: 21963936
Drug: HIV-1 gp120/NefTat
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 gp120/NefTat vaccine with AS02A adjuvant
Study: 19948278
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy (VPDT)
Study: 11238754
Drug: 750 mL
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mL red wine
Study: 11238754
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g fried onions
Study: 11238754
Drug: 375 mL
Normalized name: isopropyl alcohol 0.0375 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mL black tea
Study: 15338492
Drug: Pamidronate 45
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate 45 mg
Study: 2179802
Drug: Chlorhexidine mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthrinse (0.12% chlorhexidine digluconate, 15 ml, three times a day)
Study: 408116
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 100 mg iron as ferrous glycocoll sulphate in micropellets
Study: 408116
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 50 mg iron as ferrous glycocoll sulphate in micropellets
Study: 408116
Drug: Iron preparation
Normalized name: IRON PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron preparation given at the end of breakfast
Study: 408116
Drug: Fasting absorption
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting absorption measurement
Study: 28073036
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate solution 800mL the night before and 400mL 2h prior to operation
Study: 28073036
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate solution
Study: 25957793
Drug: Daily lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily lipid-based nutrient supplement
Study: 21801246
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of L. reuteri in stool in the first week of life
Study: 19905885
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (Exubera)
Study: 10589362
Drug: Infliximab in
Normalized name: infliximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab in combination with methotrexate (MTX)
Study: 10589362
Drug: Infliximab with
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab with high-dose MTX
Study: 8735175
Drug: Doxazosin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (dose 2 to 16 mg)
Study: 8735175
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) (dose 25 to 50 mg)
Study: 1929337
Drug: Ampicillin-sulbactam (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin-sulbactam (750 mg orally twice daily for 10 days)
Study: 1929337
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g intramuscularly) and probenecid (1 g orally), followed by doxycycline (100 mg orally twice daily for 10 days)
Study: 29323932
Drug: BrAC 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: BrAC 0.08 g/210 L
Study: 29323932
Drug: BrAC 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BrAC 0.10 g/210 L
Study: 29323932
Drug: BrAC 0.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: BrAC 0.00 g/210 L
Study: 26354331
Drug: Physicians' choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physicians' choice therapy (standard chemo‐ or endocrine therapy) with or without additional HER2‐targeted therapy with lapatinib (DETECT III trial)
Study: 26354331
Drug: Everolimus and
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus and standard endocrine therapy (DETECT IVa)
Study: 26354331
Drug: Dual HER2-targeted
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dual HER2-targeted therapy (trastuzumab plus pertuzumab) plus either endocrine or chemotherapy (DETECT V/CHEVENDO trial)
Study: 18755361
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment combining a vitamin D derivative and a strong glucocorticoid
Study: 18755361
Drug: Long-established pharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-established pharmaceuticals (cignolin, tar preparations, glucocorticoids)
Study: 18755361
Drug: Newer topical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer topical agents (vitamin A and D derivatives)
Study: 18755361
Drug: Agents directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agents directed at tumor necrosis factor alpha, Toll-like receptors, and neutrophils
Study: 14501738
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose human chorionic gonadotropin (HCG)
Study: 31547939
Drug: Oral N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral N-acetylcysteine
Study: 9120179
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin plus oral N-acetylcysteine
Study: 8468108
Drug: ITF 282
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF 282 (60 mg iron/day, 2 tablets)
Study: 8468108
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (105 mg iron/day, 1 tablet)
Study: 31620931
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus trastuzumab and chemotherapy
Study: 26473300
Drug: Nitazoxanide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (500 mg twice daily)
Study: 9600579
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg oral m-CPP
Study: 6439699
Drug: Mixed beam
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed beam radiation therapy
Study: 6350243
Drug: Photon control
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photon control treatment
Study: 29176402
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day hydrocortisone
Study: 29176402
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day hydrocortisone
Study: 26335669
Drug: Kineflex‐L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kineflex‐L
Study: 26335669
Drug: Serum ion
Normalized name: Sulfate ion
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ion analysis (Kineflex‐L subgroup)
Study: 20153030
Drug: Medium-dose extract
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose extract (4.8 microg Amb a 1/d)
Study: 20153030
Drug: High-dose extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose extract (48 microg Amb a 1/d)
Study: 18589036
Drug: 500‐mL water
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mL water preload
Study: 15947768
Drug: TEE-guided cardioversion
Normalized name: ADAPTER,VALVED TEE 22MM #1009
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEE-guided cardioversion with oral anticoagulation
Study: 10805055
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/day for 3 months)
Study: 8651963
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CsA) at 3 mg/kg/day
Study: 1299483
Drug: 1 gm
Normalized name: Ifex 1 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm of tribasic sodium phosphate four times daily for 3 days
Study: 1299483
Drug: Glucose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose placebo four times daily for 3 days
Study: 27494570
Drug: LNG-IUS 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS 8 (average levonorgestrel release rate approximately 8 μg/24 h over the first year, total content 13.5 mg)
Study: 27494570
Drug: EE/DRSP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/DRSP (30 μg ethinyl estradiol/3 mg drospirenone)
Study: 19995925
Drug: Raltegravir-based highly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir-based highly active antiretroviral therapy (HAART)
Study: 17599884
Drug: Hypothermic cardioplegic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic cardioplegic solution (HCS)
Study: 16239366
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium (25 mg)
Study: 16239366
Drug: Perindopril erbumine
Normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perindopril erbumine (2 mg)
Study: 2668129
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of SMS 201-995 at 25 micrograms/h
Study: 2668129
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of SMS 201-995 at 50 micrograms every 12 hours
Study: 2668129
Drug: Subcutaneous SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous SMS 201-995 administered by patients at home during open follow-up study
Study: 7240437
Drug: Aspirin (975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (975 mg administered four times a day, total daily dose 3.9 Gm)
Study: 7240437
Drug: Oxaprozin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaprozin (1200 mg once a day)
Study: 28474783
Drug: Peri-implant probing
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-implant probing
Study: 31325382
Drug: Implant design
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant design (with/without platform switching)
Study: 15850497
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of oral glucosamine sulphate (GS)
Study: 12456918
Drug: Bladder augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder augmentation using intestinal segments in myelomeningocele patients
Study: 12456918
Drug: Bladder augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder augmentation in bladder exstrophy patients
Study: 10839045
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of educative‐supportive system of care and behavior modification (Condition 1)
Study: 1892197
Drug: Prophylactic antibiotic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotic
Study: 31857780
Drug: Modified bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified bismuth-containing quadruple therapy (mBCQT) for 2 weeks
Study: 31857780
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (CT) for 2 weeks
Study: 31857780
Drug: Modified bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified bismuth-containing quadruple therapy (mBCQT)
Study: 25395221
Drug: In-Home Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-Home Cognitive Behavioral Therapy (IH-CBT) plus home visiting (n = 47)
Study: 24268907
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid gel
Study: 22166954
Drug: Sucromalt (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucromalt (30 g)
Study: 22166954
Drug: Inulin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (15 g)
Study: 16697124
Drug: Amantadine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (300 mg/day)
Study: 19756426
Drug: Misoprostol suppositories
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol suppositories
Study: 14656921
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (ACEI) group, n=19
Study: 10626195
Drug: 5-fluorouracil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (500 mg/m2/day by continuous intravenous infusion for 5 days) combined with cisplatin (80 mg/m2 intravenously on the 1st day)
Study: 2041004
Drug: Flumazenil (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.01 mg/kg)
Study: 25780462
Drug: Doxapram (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram (1 mg/kg)
Study: 24659140
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stable medication only)
Study: 18345521
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (cetrorelix acetate 0.25 mg) administered when follicles reached > or =14 mm
Study: 18345521
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (leuprolide acetate) in a long protocol
Study: 10027580
Drug: Low-molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular weight heparin (tinzaparin) for 3 weeks
Study: 1799911
Drug: Nitro-Dur Transdermal
Normalized name: Nitro-Dur Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitro-Dur Transdermal Infusion System
Study: 1799911
Drug: Transderm-Nitro Transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transderm-Nitro Transdermal Therapeutic System
Study: 6230209
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate - 50 mg b.i.d.
Study: 29246960
Drug: omega‐3 ethyl‐ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega‐3 ethyl‐ester (1.86 g of eicosapentaenoic acid and 1.5 g of docosahexaenoic acid daily)
Study: 26036082
Drug: Standard combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combined treatment (including pharmacotherapy, massage, and therapeutic physical culture exercises)
Study: 23143710
Drug: Twin-mix (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twin-mix (1.8 ml 2% lignocaine with 1:200,000 epinephrine + 1 ml of 4 mg dexamethasone)
Study: 19837909
Drug: Cinacalcet 30
Normalized name: cinacalcet 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet 30 mg twice daily, increasing to 50 mg twice daily during the 12-week titration if serum calcium levels were 10.3 mg/dl or higher
Study: 16946029
Drug: Adenosine receptor
Normalized name: Adenosine receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine receptor antagonism with aminophylline (Aph)
Study: 14724146
Drug: Omeprazole triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole triple therapy (HpE group)
Study: 14724146
Drug: Omeprazole with
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole with placebo antibiotics (Hp+ group)
Study: 9402119
Drug: Rectal tube
Normalized name: rectal tube
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal tube placement
Study: 31780570
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg every 3 weeks, typically for ≤12 months) combined with front-line chemotherapy (carboplatin/paclitaxel)
Study: 31780570
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg) with chemotherapy
Study: 14727235
Drug: RCT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT plus amifostine (300 mg/m(2) daily intravenous infusion)
Study: 1852797
Drug: Training twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training twice per week (n = 12)
Study: 30862193
Drug: TX-004HR (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TX-004HR (4, 10, or 25 μg)
Study: 28653345
Drug: Intravenous bimagrumab
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bimagrumab 30 mg/kg
Study: 17307412
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration before transfer to catheterization laboratory (27 patients)
Study: 17307412
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration immediately before PPCI (32 patients)
Study: 11685730
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and exisulind combination therapy
Study: 9059766
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) with a low-calorie diet and metformin 1,700 mg/day
Study: 30905926
Drug: Metformin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin combined group
Study: 30905926
Drug: Insulin group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin group (Control)
Study: 18500521
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg twice per day, 4 days before and on the day of chemotherapy (cohort 2)
Study: 18500521
Drug: Dexamethasone 16
Normalized name: dexamethasone 16 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 16 mg twice per day, 4 days before and on the day of chemotherapy (cohort 3)
Study: 16702889
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose venlafaxine ER (mean dose = 309 mg/d)
Study: 16702889
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose venlafaxine ER (mean dose = 148 mg/d)
Study: 16702889
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose venlafaxine ER
Study: 16702889
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose venlafaxine ER
Study: 8321736
Drug: All dosage
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosage groups of ramipril and enalapril
Study: 3759915
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral dose of oxazepam in capsule form
Study: 3759915
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oral dose of oxazepam in tablet form
Study: 27629738
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative antibiotic therapy (Group II, n = 25)